Latest Content

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration.

The FDA granted review to a supplemental biologics license application for Opdivo plus chemo for previously untreated stage 3/4 classical Hodgkin lymphoma.

I struggle to understand why people support policies and leaders that make healthcare less affordable and accessible for everyone.

CURE spoke with Dr. Dickran Kazandjian about why MRD matters for patients with multiple myeloma.

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm versus 95.7% in the no MRI arm, researchers reported.

Enhertu and Perjeta led to better quality-of-life and less side effects than standard-of-care among patients with HER2+ advanced or metastatic breast.

Adding radiation before surgery with Keytruda increased immune cells in tumors and led to encouraging responses in people with early-stage breast cancer.

Tecentriq numerically increased the rates of chemotherapy-induced ovarian failure compared with chemotherapy alone for patients with triple-negative breast cancer.

Verzenio showed meaningful improvement for some patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 treatment.

Dan, diagnosed with stage 4 pancreatic cancer, shares his journey to remission and insights on clinical trials and patient advocacy.

Nuvisertib plus momelotinib is safe and generated improvements in symptom burden, spleen volume, and anemia outcomes in relapsed/refractory myelofibrosis.

Giredestrant generated improved outcomes over standard endocrine therapy in patients with ER+/HER2–, medium- and high-risk early breast cancer.

Progression-free survival was not statistically significant with Trodelvy versus chemotherapy as first-line treatment in HR+/HER2– metastatic breast cancer.